Tanya Dorff, Associate Professor of Clinical Medicine at USC Keck School of Medicine, shared a post on X:
“Thoughtful breakdown of challenges in APMN prostate cancer by Dr Elisabeth Heath. Bottom line is ADT monotherapy is not enough for the majority.
Early intensification, in some cases even triplet, pays dividends for patients in terms of cancer control.”
More from Tanya Dorff on OncoDaily.